Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Moutinho M, Codocedo JF, Puntambekar SS, Landreth GE.

Annu Rev Pharmacol Toxicol. 2018 Sep 12. doi: 10.1146/annurev-pharmtox-010818-021807. [Epub ahead of print]

PMID:
30208281
2.

HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage.

Loppi S, Kolosowska N, Kärkkäinen O, Korhonen P, Huuskonen M, Grubman A, Dhungana H, Wojciechowski S, Pomeshchik Y, Giordano M, Kagechika H, White A, Auriola S, Koistinaho J, Landreth G, Hanhineva K, Kanninen K, Malm T.

Brain Behav Immun. 2018 Oct;73:670-681. doi: 10.1016/j.bbi.2018.07.021. Epub 2018 Jul 29.

PMID:
30063972
3.

Active PSF shaping and adaptive optics enable volumetric localization microscopy through brain sections.

Mlodzianoski MJ, Cheng-Hathaway PJ, Bemiller SM, McCray TJ, Liu S, Miller DA, Lamb BT, Landreth GE, Huang F.

Nat Methods. 2018 Aug;15(8):583-586. doi: 10.1038/s41592-018-0053-8. Epub 2018 Jul 16.

PMID:
30013047
4.

Pharmacological Inhibition of ERK Signaling Rescues Pathophysiology and Behavioral Phenotype Associated with 16p11.2 Chromosomal Deletion in Mice.

Pucilowska J, Vithayathil J, Pagani M, Kelly C, Karlo JC, Robol C, Morella I, Gozzi A, Brambilla R, Landreth GE.

J Neurosci. 2018 Jul 25;38(30):6640-6652. doi: 10.1523/JNEUROSCI.0515-17.2018. Epub 2018 Jun 22.

PMID:
29934348
5.

The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease.

Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von Saucken VE, Williams RY, Karlo JC, Moutinho M, Xu G, Ransohoff RM, Lamb BT, Landreth GE.

Mol Neurodegener. 2018 Jun 1;13(1):29. doi: 10.1186/s13024-018-0262-8.

6.
7.

Targeting Neuroinflammation to Treat Alzheimer's Disease.

Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzériat K, Dansokho C, Dierkes T, Gelders G, Heneka MT, Hoeijmakers L, Hoffmann A, Iaccarino L, Jahnert S, Kuhbandner K, Landreth G, Lonnemann N, Löschmann PA, McManus RM, Paulus A, Reemst K, Sanchez-Caro JM, Tiberi A, Van der Perren A, Vautheny A, Venegas C, Webers A, Weydt P, Wijasa TS, Xiang X, Yang Y.

CNS Drugs. 2017 Dec;31(12):1057-1082. doi: 10.1007/s40263-017-0483-3. Review.

8.

TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy.

Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, Kokiko-Cochran ON, Crish SD, Lasagna-Reeves CA, Ransohoff RM, Landreth GE, Lamb BT.

Mol Neurodegener. 2017 Oct 16;12(1):74. doi: 10.1186/s13024-017-0216-6.

9.

Chronic impairment of ERK signaling in glutamatergic neurons of the forebrain does not affect spatial memory retention and LTP in the same manner as acute blockade of the ERK pathway.

Vithayathil J, Pucilowska J, Friel D, Landreth GE.

Hippocampus. 2017 Dec;27(12):1239-1249. doi: 10.1002/hipo.22769. Epub 2017 Sep 7.

PMID:
28833860
10.

TREM2 in Neurodegenerative Diseases.

Jay TR, von Saucken VE, Landreth GE.

Mol Neurodegener. 2017 Aug 2;12(1):56. doi: 10.1186/s13024-017-0197-5. Review.

11.

Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Mast N, Saadane A, Valencia-Olvera A, Constans J, Maxfield E, Arakawa H, Li Y, Landreth G, Pikuleva IA.

Neuropharmacology. 2017 Sep 1;123:465-476. doi: 10.1016/j.neuropharm.2017.06.026. Epub 2017 Jun 24.

12.

Aβ Extraction from Murine Brain Homogenates.

Casali BT, Landreth GE.

Bio Protoc. 2016 Apr 20;6(8). pii: e1787. doi: 10.21769/BioProtoc.1787.

13.

Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Moutinho M, Landreth GE.

J Lipid Res. 2017 Oct;58(10):1937-1949. doi: 10.1194/jlr.R075556. Epub 2017 Mar 6. Review.

PMID:
28264880
14.

Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.

Mariani MM, Malm T, Lamb R, Jay TR, Neilson L, Casali B, Medarametla L, Landreth GE.

Sci Rep. 2017 Feb 16;7:42270. doi: 10.1038/srep42270.

15.

Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?

Piirainen S, Youssef A, Song C, Kalueff AV, Landreth GE, Malm T, Tian L.

Neurosci Biobehav Rev. 2017 Jun;77:148-164. doi: 10.1016/j.neubiorev.2017.01.046. Epub 2017 Feb 6. Review.

PMID:
28185874
16.

Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease.

Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE.

J Neurosci. 2017 Jan 18;37(3):637-647. doi: 10.1523/JNEUROSCI.2110-16.2016.

17.

Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system.

Garcia-Mesa Y, Jay TR, Checkley MA, Luttge B, Dobrowolski C, Valadkhan S, Landreth GE, Karn J, Alvarez-Carbonell D.

J Neurovirol. 2017 Feb;23(1):47-66. doi: 10.1007/s13365-016-0499-3. Epub 2016 Nov 21.

18.

Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy.

Huuskonen MT, Loppi S, Dhungana H, Keksa-Goldsteine V, Lemarchant S, Korhonen P, Wojciechowski S, Pollari E, Valonen P, Koponen J, Takashima A, Landreth G, Goldsteins G, Malm T, Koistinaho J, Kanninen KM.

Sci Rep. 2016 Sep 14;6:33176. doi: 10.1038/srep33176.

19.

A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects.

Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE.

Alzheimers Dement (N Y). 2016 Jun 17;2(2):110-120. doi: 10.1016/j.trci.2016.06.001. eCollection 2016 Jun.

20.

Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Andreasson KI, Bachstetter AD, Colonna M, Ginhoux F, Holmes C, Lamb B, Landreth G, Lee DC, Low D, Lynch MA, Monsonego A, O'Banion MK, Pekny M, Puschmann T, Russek-Blum N, Sandusky LA, Selenica ML, Takata K, Teeling J, Town T, Van Eldik LJ.

J Neurochem. 2016 Sep;138(5):653-93. doi: 10.1111/jnc.13667. Review. Erratum in: J Neurochem. 2017 Apr;141(1):151.

21.

Simvastatin inhibits protein isoprenylation in the brain.

Ostrowski SM, Johnson K, Siefert M, Shank S, Sironi L, Wolozin B, Landreth GE, Ziady AG.

Neuroscience. 2016 Aug 4;329:264-74. doi: 10.1016/j.neuroscience.2016.04.053. Epub 2016 May 12.

22.

LXR Regulation of Brain Cholesterol: From Development to Disease.

Courtney R, Landreth GE.

Trends Endocrinol Metab. 2016 Jun;27(6):404-414. doi: 10.1016/j.tem.2016.03.018. Epub 2016 Apr 21. Review.

23.

Retinoids and motor neuron disease: Potential role in amyotrophic lateral sclerosis.

Riancho J, Berciano MT, Ruiz-Soto M, Berciano J, Landreth G, Lafarga M.

J Neurol Sci. 2016 Jan 15;360:115-20. doi: 10.1016/j.jns.2015.11.058. Epub 2015 Dec 2. Review.

PMID:
26723986
24.

Lipidated APOE has effects on cognitive function that are independent of amyloid-β pathology.

Corona A, Landreth G.

Brain. 2015 Dec;138(Pt 12):3470-2. doi: 10.1093/brain/awv300. No abstract available.

PMID:
26598491
25.

Peripheral macrophages not ADept at amyloid clearance.

Jay T, Lamb B, Landreth G.

J Exp Med. 2015 Oct 19;212(11):1758. doi: 10.1084/jem.21211insight5. No abstract available.

26.

ERK Signaling Is Essential for Macrophage Development.

Richardson ET, Shukla S, Nagy N, Boom WH, Beck RC, Zhou L, Landreth GE, Harding CV.

PLoS One. 2015 Oct 7;10(10):e0140064. doi: 10.1371/journal.pone.0140064. eCollection 2015.

27.

ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Corona AW, Kodoma N, Casali BT, Landreth GE.

J Neuroimmune Pharmacol. 2016 Mar;11(1):61-72. doi: 10.1007/s11481-015-9627-8. Epub 2015 Jul 15.

PMID:
26175148
28.

Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.

Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE.

J Biol Chem. 2015 Aug 28;290(35):21591-602. doi: 10.1074/jbc.M115.652008. Epub 2015 Jul 10.

29.

ERK2 Alone Drives Inflammatory Pain But Cooperates with ERK1 in Sensory Neuron Survival.

O'Brien DE, Alter BJ, Satomoto M, Morgan CD, Davidson S, Vogt SK, Norman ME, Gereau GB, Demaro JA 3rd, Landreth GE, Golden JP, Gereau RW 4th.

J Neurosci. 2015 Jun 24;35(25):9491-507. doi: 10.1523/JNEUROSCI.4404-14.2015.

30.

Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.

Casali BT, Corona AW, Mariani MM, Karlo JC, Ghosal K, Landreth GE.

J Neurosci. 2015 Jun 17;35(24):9173-81. doi: 10.1523/JNEUROSCI.1000-15.2015.

31.

Dentate Gyrus Development Requires ERK Activity to Maintain Progenitor Population and MAPK Pathway Feedback Regulation.

Vithayathil J, Pucilowska J, Goodnough LH, Atit RP, Landreth GE.

J Neurosci. 2015 Apr 29;35(17):6836-48. doi: 10.1523/JNEUROSCI.4196-14.2015.

32.

Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.

Savage JC, Jay T, Goduni E, Quigley C, Mariani MM, Malm T, Ransohoff RM, Lamb BT, Landreth GE.

J Neurosci. 2015 Apr 22;35(16):6532-43. doi: 10.1523/JNEUROSCI.4586-14.2015.

33.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

34.

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.

Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT.

J Exp Med. 2015 Mar 9;212(3):287-95. doi: 10.1084/jem.20142322. Epub 2015 Mar 2.

35.

The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway.

Pucilowska J, Vithayathil J, Tavares EJ, Kelly C, Karlo JC, Landreth GE.

J Neurosci. 2015 Feb 18;35(7):3190-200. doi: 10.1523/JNEUROSCI.4864-13.2015.

36.

Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions.

Seaberg B, Henslee G, Wang S, Paez-Colasante X, Landreth GE, Rimer M.

Mol Cell Biol. 2015 Apr;35(7):1238-53. doi: 10.1128/MCB.01071-14. Epub 2015 Jan 20.

37.

Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.

Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE.

J Neuroinflammation. 2015 Jan 16;12:7. doi: 10.1186/s12974-014-0229-9.

38.

The evolving biology of microglia in Alzheimer's disease.

Malm TM, Jay TR, Landreth GE.

Neurotherapeutics. 2015 Jan;12(1):81-93. doi: 10.1007/s13311-014-0316-8. Review.

39.

Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway.

Lee S, Xu G, Jay TR, Bhatta S, Kim KW, Jung S, Landreth GE, Ransohoff RM, Lamb BT.

J Neurosci. 2014 Sep 10;34(37):12538-46. doi: 10.1523/JNEUROSCI.0853-14.2014.

40.

Nuclear receptors in neurodegenerative diseases.

Skerrett R, Malm T, Landreth G.

Neurobiol Dis. 2014 Dec;72 Pt A:104-16. doi: 10.1016/j.nbd.2014.05.019. Epub 2014 May 27. Review.

41.

Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J.

Neurobiol Aging. 2014 Sep;35(9):2091-5. doi: 10.1016/j.neurobiolaging.2014.03.029. Epub 2014 Apr 2.

42.

Evidence for impaired amyloid β clearance in Alzheimer's disease.

Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE.

Alzheimers Res Ther. 2013 Jul 12;5(4):33. doi: 10.1186/alzrt187. eCollection 2013. Review.

43.

Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA.

Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.

44.

In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis.

Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM.

Mol Neurodegener. 2013 Apr 19;8:13. doi: 10.1186/1750-1326-8-13.

45.

The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model.

Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A, Landreth GE.

Cancer Chemother Pharmacol. 2013 Apr;71(4):929-36. doi: 10.1007/s00280-013-2084-2. Epub 2013 Jan 29.

PMID:
23358645
46.

Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.

Cameron B, Tse W, Lamb R, Li X, Lamb BT, Landreth GE.

J Neurosci. 2012 Oct 24;32(43):15112-23. doi: 10.1523/JNEUROSCI.1729-12.2012.

47.
48.
49.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

50.

Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.

Lee CY, Tse W, Smith JD, Landreth GE.

J Biol Chem. 2012 Jan 13;287(3):2032-44. doi: 10.1074/jbc.M111.295451. Epub 2011 Nov 30.

Supplemental Content

Loading ...
Support Center